Emeryville, California, United StatesFounded 201722+ employeesPrivate
$12.9M raisedSeed· last: seed (May 2024)· 5 rounds
Backed by(2 investors)
The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.
